GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaleaf Holdings Inc (OTCPK:CURLF) » Definitions » EV-to-Revenue

Curaleaf Holdings (Curaleaf Holdings) EV-to-Revenue : 3.43 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Curaleaf Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Curaleaf Holdings's enterprise value is $4,652 Mil. Curaleaf Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $1,356 Mil. Therefore, Curaleaf Holdings's EV-to-Revenue for today is 3.43.

The historical rank and industry rank for Curaleaf Holdings's EV-to-Revenue or its related term are showing as below:

CURLF' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.97   Med: 4.84   Max: 63.63
Current: 3.47

During the past 10 years, the highest EV-to-Revenue of Curaleaf Holdings was 63.63. The lowest was -0.97. And the median was 4.84.

CURLF's EV-to-Revenue is ranked worse than
65.01% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.335 vs CURLF: 3.47

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Curaleaf Holdings's stock price is $5.23. Curaleaf Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.86. Therefore, Curaleaf Holdings's PS Ratio for today is 2.81.


Curaleaf Holdings EV-to-Revenue Historical Data

The historical data trend for Curaleaf Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaleaf Holdings EV-to-Revenue Chart

Curaleaf Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.89 13.41 5.65 3.11 2.92

Curaleaf Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 2.32 3.10 2.92 3.59

Competitive Comparison of Curaleaf Holdings's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curaleaf Holdings's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Curaleaf Holdings's EV-to-Revenue falls into.



Curaleaf Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Curaleaf Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4652.400/1355.953
=3.43

Curaleaf Holdings's current Enterprise Value is $4,652 Mil.
Curaleaf Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,356 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curaleaf Holdings  (OTCPK:CURLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Curaleaf Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=5.23/1.861
=2.81

Curaleaf Holdings's share price for today is $5.23.
Curaleaf Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.86.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curaleaf Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Curaleaf Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Curaleaf Holdings (Curaleaf Holdings) Business Description

Traded in Other Exchanges
Address
420 Lexington Avenue, Suite 2035, New York, NY, USA, 10170-0052
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 18 states. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.